Showing 3661-3670 of 5646 results for "".
- Heidelberg Engineering Receives FDA Clearance for Spectralis Flex Module for Supine Imaginghttps://modernod.com/news/heidelberg-engineering-receives-fda-clearance-for-spectralis-flex-module-for-supine-imaging/2482486/Heidelberg Engineering has received FDA clearance for its Spectralis Flex Module, a multimodal diagnostic imaging platform. The new module is designed specifically for imaging the posterior segment of both pediatric and adult patients in a supine position, addressing a need for patients unab
- FDA Approves Bausch + Lomb's enVista Envy Full Range of Vision IOLhttps://modernod.com/news/bausch-lomb-announces-fda-approval-of-envista-envy-full-range-of-vision-iol/2482482/Bausch + Lomb announced that the FDA has approved the enVista Envy full range of vision IOL. The new lens is built on the enVista IOL platform and is designed to offer patients a continuous range of vision while providing excellent tolerance for dysphotopsia.
- RetinaLyze Launches Advanced Glaucoma Progression AIhttps://modernod.com/news/retinalyze-launches-advanced-glaucoma-progression-ai/2482480/RetinaLyze has introduced the Advanced Glaucoma Progression AI. Central to this technology is the 'Glaucoma Index of Progression' (GIP), a tool designed to provide a stable and consistent method for tracking glaucoma progression over time. Glaucoma, often referred to a
- Melt Announces Completion of Patient Dosing in Phase 3 Study of MELT-300 for Procedural Sedationhttps://modernod.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/Melt Pharmaceuticals announced the completion of patient dosing in its pivotal phase 3 clinical trial. This study evaluates the safety and efficacy of MELT-300, the company's lead product candidate, for providing non-intravenous, non-opioid sedation during cataract surgery. MELT-300
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show
- Marinomed Biotech Reports Promising Phase 2 Results for Tacrosolv Eye Drops in Treating Allergic Rhinoconjunctivitishttps://modernod.com/news/marinomed-biotech-reports-promising-phase-2-results-for-tacrosolv-eye-drops-in-treating-allergic-rhinoconjunctivitis/2482473/Marinomed Biotech has announced clinical data from its phase 2 dose-finding clinical trial on Tacrosolv, a novel eye drop formulation for treating allergic rhinoconjunctivitis. The results, now published in the peer-reviewed journal Clinical Ophthalmology, indicate that Tacrosolv, formulated usin
- Aldeyra Resubmits NDA for Topical Ocular Reproxalap for Dry Eye Diseasehttps://modernod.com/news/aldeyra-resubmits-nda-for-topical-ocular-reproxalap-for-dry-eye-disease/2482469/Aldeyra Therapeutics announced the resubmission of a new drug application (NDA) to the FDA for its investigational topical drug, reproxalap, which is intended to treat the signs and symptoms of dry eye disease. The resubmission follows a recent FDA-requested trial that demonst
- Rayner Announces First RayOne Galaxy Implantations in the UShttps://modernod.com/news/rayner-announces-first-rayone-galaxy-implantations-in-the-us/2482467/Rayner has announced the implantation of the first IOL in the RayOne Galaxy FDA-approved investigational device exemption (IDE) study. This milestone marks the beginning of a prospective, multicenter, randomized, masked, and active-controlled study aimed at evaluating the RayOne Galaxy
- Bausch + Lomb Launches Opal Digital Marketplace in the UShttps://modernod.com/news/bausch-lomb-launches-opal-digital-marketplace-in-the-us/2482465/Bausch + Lomb announced the US launch of Opal, a new digital e-commerce marketplace designed to enhance efficiency for eye care practices while improving the patient experience. The platform provides a streamlined and user-friendly ordering process for Bausch + Lomb’s contact lens
- Andreas Pecher to Succeed Dr. Karl Lamprecht as President and CEO of Carl Zeiss AGhttps://modernod.com/news/andreas-pecher-to-succeed-dr-karl-lamprecht-as-president-and-ceo-of-carl-zeiss-ag/2482461/After nearly two decades of leadership at Carl Zeiss AG, Karl Lamprecht, the current President and CEO, has announced that he will not be extending his contract, which is set to expire in the spring of 2025. Andreas Pecher was appointed the company's new President and CEO, effective Apri